ZBB Considered Useless By NCI Staff (Privately)’ New Approach Groups Program Into Four Categories
In Brief: Upton Okays Laetrile Clinical Trials, To Seek Protocols From Clinicians For IND Request
Regulatory Agencies Get Data For Action Against One Of World’s Most Widely Used Carcinogens
Change In Method Of Counting Cancer Incidence Results In More Attributed To Work Hazards
IG Report Clears Shubik Of Conflict Of Interest Change
Trending Stories
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- No need for a speculum? A new era of HPV screening
- Most Favored Nation drug pricing could put China on top
- Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
A kit for at-home unsupervised self-collection clears FDA finish line









